Meanwhile, shares of Bristol Myers Squibb, makers of recently approved schizophrenia treatment Cobenfy, soared 12%. Shares of AbbVie (ABBV) plummeted Monday after the company said its schizophrenia ...
Some results have been hidden because they may be inaccessible to you